#1i Clinical trials for the new antidiabetic SGLT-2 inhibitor ‘Enavogliflozin’ in development by Daewoong Pharmaceutical are gaining speed.

One of the three Phase III clinical trials is already complete, and the remaining two are also nearing their final stages after completing patient recruitment.

With such progress, the industry expects the authorities to grant marketing authorization for Enavogliflozin within the first half of next year, then be released in 2023.

◆Phase III trial on two-drug combo complete… trials on monotherapy and three-drug combo also in final stages

According to the industry on the 10th, Daewoong Pharmaceutical had recently com